247 related articles for article (PubMed ID: 17969201)
1. Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study.
Klintmalm GB; Washburn WK; Rudich SM; Heffron TG; Teperman LW; Fasola C; Eckhoff DE; Netto GJ; Katz E
Liver Transpl; 2007 Nov; 13(11):1521-31. PubMed ID: 17969201
[TBL] [Abstract][Full Text] [Related]
2. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C.
Klintmalm GB; Davis GL; Teperman L; Netto GJ; Washburn K; Rudich SM; Pomfret EA; Vargas HE; Brown R; Eckhoff D; Pruett TL; Roberts J; Mulligan DC; Charlton MR; Heffron TG; Ham JM; Douglas DD; Sher L; Baliga PK; Kinkhabwala M; Koneru B; Abecassis M; Millis M; Jennings LW; Fasola CG
Liver Transpl; 2011 Dec; 17(12):1394-403. PubMed ID: 21850690
[TBL] [Abstract][Full Text] [Related]
3. Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil.
Washburn K; Speeg KV; Esterl R; Cigarroa F; Pollack M; Tourtellot C; Maxwell P; Halff G
Transplantation; 2001 Nov; 72(10):1675-9. PubMed ID: 11726831
[TBL] [Abstract][Full Text] [Related]
4. A multicenter, open-label, comparative trial of two daclizumab dosing strategies vs. no antibody induction in combination with tacrolimus, mycophenolate mofetil, and steroids for the prevention of acute rejection in simultaneous kidney-pancreas transplant recipients: interim analysis.
Stratta RJ; Alloway RR; Hodge E; Lo A;
Clin Transplant; 2002 Feb; 16(1):60-8. PubMed ID: 11982617
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year.
Kato T; Gaynor JJ; Yoshida H; Montalvano M; Takahashi H; Pyrsopoulos N; Nishida S; Moon J; Selvaggi G; Levi D; Ruiz P; Schiff E; Tzakis A
Transplantation; 2007 Oct; 84(7):829-35. PubMed ID: 17984834
[TBL] [Abstract][Full Text] [Related]
6. A prospective randomized open study in liver transplant recipients: daclizumab, mycophenolate mofetil, and tacrolimus versus tacrolimus and steroids.
Otero A; Varo E; de Urbina JO; Martín-Vivaldi R; Cuervas-Mons V; González-Pinto I; Rimola A; Bernardos A; Otero S; Maldonado J; Herrero JI; Barrao E; Domínguez-Granados R
Liver Transpl; 2009 Nov; 15(11):1542-52. PubMed ID: 19877219
[TBL] [Abstract][Full Text] [Related]
7. Randomized, multicenter trial comparing tacrolimus plus mycophenolate mofetil to tacrolimus plus steroids in hepatitis C virus-positive recipients of living donor liver transplantation.
Takada Y; Kaido T; Asonuma K; Sakurai H; Kubo S; Kiuchi T; Inomata Y; Isaji S; Tsumura H; Teramukai S; Matsubara Y; Sakabayashi S; Uemoto S
Liver Transpl; 2013 Aug; 19(8):896-906. PubMed ID: 23696054
[TBL] [Abstract][Full Text] [Related]
8. Corticosteroid-Sparing and Optimization of Mycophenolic Acid Exposure in Liver Transplant Recipients Receiving Mycophenolate Mofetil and Tacrolimus: A Randomized, Multicenter Study.
Saliba F; Rostaing L; Gugenheim J; Durand F; Radenne S; Leroy V; Neau-Cransac M; Calmus Y; Salamé E; Pageaux GP; Duvoux C; Taguieva N; Sinnasse-Raymond G; Sebagh M; Samuel D; Marquet P
Transplantation; 2016 Aug; 100(8):1705-13. PubMed ID: 27454919
[TBL] [Abstract][Full Text] [Related]
9. Initial clinical experience with interleukin-2 receptor antagonist induction in combination with tacrolimus, mycophenolate mofetil and steroids in simultaneous kidney-pancreas transplantation.
Lo A; Stratta RJ; Alloway RR; Egidi MF; Shokouh-Amiri MH; Grewal HP; Gaber LW; Gaber AO
Transpl Int; 2001 Dec; 14(6):396-404. PubMed ID: 11793037
[TBL] [Abstract][Full Text] [Related]
10. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study.
Boillot O; Mayer DA; Boudjema K; Salizzoni M; Gridelli B; Filipponi F; Trunecka P; Krawczyk M; Clavien PA; Ducerf C; Margarit C; Margreiter R; Pallardo JM; Hoeckerstedt K; Pageaux GP
Liver Transpl; 2005 Jan; 11(1):61-7. PubMed ID: 15690537
[TBL] [Abstract][Full Text] [Related]
11. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation.
Rostaing L; Cantarovich D; Mourad G; Budde K; Rigotti P; Mariat C; Margreiter R; Capdevilla L; Lang P; Vialtel P; Ortuño-Mirete J; Charpentier B; Legendre C; Sanchez-Plumed J; Oppenheimer F; Kessler M;
Transplantation; 2005 Apr; 79(7):807-14. PubMed ID: 15818323
[TBL] [Abstract][Full Text] [Related]
12. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study.
Neuberger JM; Mamelok RD; Neuhaus P; Pirenne J; Samuel D; Isoniemi H; Rostaing L; Rimola A; Marshall S; Mayer AD;
Am J Transplant; 2009 Feb; 9(2):327-36. PubMed ID: 19120077
[TBL] [Abstract][Full Text] [Related]
13. Daclizumab induction and maintenance steroid-free immunosuppression with mycophenolate mofetil and tacrolimus to prevent acute rejection of hepatic allografts.
Figueras J; Prieto M; Bernardos A; Rimola A; Suárez F; de Urbina JO; Cuervas-Mons V; Mata Mde L
Transpl Int; 2006 Aug; 19(8):641-8. PubMed ID: 16827681
[TBL] [Abstract][Full Text] [Related]
14. Steroid-free induction and preemptive antiviral therapy for liver transplant recipients with hepatitis C: a preliminary report from a prospective randomized study.
Kato T; Yoshida H; Sadfar K; Martinez E; Nishida S; Moon J; Madariaga J; Selvaggi G; Levi D; Ruiz P; Schiff E; Tzakis A
Transplant Proc; 2005 Mar; 37(2):1217-9. PubMed ID: 15848674
[TBL] [Abstract][Full Text] [Related]
15. The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients.
Kuypers DR; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
Clin Transplant; 2003 Jun; 17(3):234-41. PubMed ID: 12780674
[TBL] [Abstract][Full Text] [Related]
16. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation.
Nelson DR; Soldevila-Pico C; Reed A; Abdelmalek MF; Hemming AW; Van der Werf WJ; Howard R; Davis GL
Liver Transpl; 2001 Dec; 7(12):1064-70. PubMed ID: 11753908
[TBL] [Abstract][Full Text] [Related]
17. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C.
Jain A; Kashyap R; Demetris AJ; Eghstesad B; Pokharna R; Fung JJ
Liver Transpl; 2002 Jan; 8(1):40-6. PubMed ID: 11799484
[TBL] [Abstract][Full Text] [Related]
18. [Daclizumab in combination with mycophenolate mofetil and a late introduction of Tacrolimus at low doses, as a therapeutic approach in the elderly renal transplant donor-recipients pairs in kidney transplant].
Gentil MA; Osuna A; Capdevilla L; Cantarell C; Pereira P; Mazuecos A; González Molina M
Nefrologia; 2008; 28(3):287-92. PubMed ID: 18590495
[TBL] [Abstract][Full Text] [Related]
19. Outcome of induction immunosuppression for liver transplantation comparing anti-thymocyte globulin, daclizumab, and corticosteroid.
Uemura T; Schaefer E; Hollenbeak CS; Khan A; Kadry Z
Transpl Int; 2011 Jul; 24(7):640-50. PubMed ID: 21429047
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and cardiovascular safety of daclizumab, mycophenolate mofetil, tacrolimus, and early steroid withdrawal in renal transplant recipients: a multicenter, prospective, pilot trial.
Abramowicz D; Vanrenterghem Y; Squifflet JP; Kuypers D; Mourad M; Meurisse M; Wissing M
Clin Transplant; 2005 Aug; 19(4):475-82. PubMed ID: 16008591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
